AA
CRNC icon

Altrafin AG’s Cerence CRNC Stock Holding History

Altrafin AG’s Portfolio CRNC Stock Details CRNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,950
Closed -$533K – 88
2021
Q4 		$533K Buy
+6,950
New +$613K 0.19% 73

Other funds holding CRNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

Altrafin AG's CRNC Position: Q1 2022 in Review

Altrafin AG sold out of Cerence (CRNC) in Q1 2022, closing a stake of 6,950 shares — an estimated $533K sold.

Altrafin AG first reported a position in CRNC in Q4 2021 and held it in 1 quarter. The position peaked at $533K in Q4 2021. 286 funds tracked by Wall St. Rank hold CRNC as of Q1 2022.

  • Altrafin AG reported no remaining Cerence position as of Q1 2022 after selling out during the quarter.
  • Altrafin AG sold 6,950 Cerence shares in Q1 2022, an estimated $533K.
  • Altrafin AG first reported a position in Cerence in Q4 2021 and held it in 1 quarter.
  • Altrafin AG's Cerence position peaked at $533K in Q4 2021.
  • 286 funds tracked by Wall St. Rank held Cerence as of Q1 2022.

Based on Altrafin AG's 13F filing for Q1 2022, filed 17 Feb 2026.